# A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects

> **NCT06556966** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 66 (actual)

## Conditions studied

- Schizophrenia
- Alzheimer's Disease Psychosis

## Interventions

- **DRUG:** LY03020
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06556966
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-19
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-02-13
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06556966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06556966, "A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06556966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*